Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer (CIMER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04220476
Recruitment Status : Withdrawn (Initiating a new study with revised Statistics.)
First Posted : January 7, 2020
Last Update Posted : September 21, 2020
Sponsor:
Information provided by (Responsible Party):
Weill Medical College of Cornell University

Brief Summary:
Women with Hormone Receptor (HR)+ Human Epidermal growth factor Receptor (HER)2- metastatic breast cancer are eligible to a randomized trial. Patients receiving standard first line therapy for metastatic HR+ Breast cancer(BC) (letrozole+palbociclib) are randomly assigned to also receive Stereotactic Body Radiation Therapy(SBRT) to each metastatic lesion.

Condition or disease Intervention/treatment Phase
Breast Cancer Radiation: Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions) Drug: Letrozole 2.5Mg Tab Drug: Palbociclib 125mg Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer
Actual Study Start Date : March 4, 2020
Estimated Primary Completion Date : December 31, 2025
Estimated Study Completion Date : December 31, 2028

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Active Comparator: ARM 1 - Letrozole and Palbociclib
Patients randomized to arm 1 will start standard Letrozole followed by Palbociclib at day 21.
Drug: Letrozole 2.5Mg Tab
All patients start standard therapy with oral letrozole (Femara), day 1 of the study.

Drug: Palbociclib 125mg
Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT.

Active Comparator: ARM 2 - Letrozole and Palbociclib + I-SBRT
Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT. Treatment may be given daily (to keep the total I-SBRT treatment time to ≤ 12 days) and lesions targeted with I-SBRT will thus be alternated each day to accommodate for the 48 hour interval between fractions.
Radiation: Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions)
Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT. They will undergo tumor Immunogenic-SBRT(I-SBRT) days 1-12 (+/-2 days, to enable inclusion of holidays). During the week preceding day 1, they will undergo simulation and planning for radiotherapy. Each oligometastatic lesion will be treated with I-SBRT every 48 hours. Treatment may be given daily (to keep the total I-SBRT treatment time to ≤ 12 days) and lesions targeted with I-SBRT will thus be alternated each day to accommodate for the 48 hour interval between fractions

Drug: Letrozole 2.5Mg Tab
All patients start standard therapy with oral letrozole (Femara), day 1 of the study.

Drug: Palbociclib 125mg
Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT.




Primary Outcome Measures :
  1. Number of subjects achieving Objective response rate (ORR) will be assessed. [ Time Frame: End of study, up to 36 months. ]
    ORR is defined as the percentage of subjects with either a confirmed complete response (CR) or partial response (PR).

  2. Number of Subjects achieving Progression free survival (PFS) [ Time Frame: End of study, up to 36 months. ]
    Progression free survival (PFS) is defined as the time from the start of study treatment until the disease progression or death.

  3. Number of subjects achieving Overall survival(OS) will be assessed. [ Time Frame: End of study, up to 36 months. ]
    OS is defined as the time from the start of treatment until death.


Secondary Outcome Measures :
  1. Serial levels of Circulating tumor DNA (ctDNA) [ Time Frame: End of study, up to 36 months. ]
    serial levels ctDNA can be an early indication of progression

  2. Circulating tumor DNA (ctDNA) levels [ Time Frame: End of study, up to 36 months. ]
    Circulating tumor DNA (ctDNA) levels will be measured to determine baseline cancer heterogeneity and its response to treatment



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Female ≥ 18 years of age pre and post-menopausal
  • Oligometastatic disease (≤ 5 sites of disease)
  • Premenopausal status is defined as either:
  • Patient had last menstrual period within the last 12 months, OR
  • If on tamoxifen or toremifene within the past 14 days, plasma estradiol and FSH must be in the premenopausal range per local normal range, OR
  • In case of therapy induced amenorrhea, plasma estradiol and/or FSH must be in the premenopausal range per local normal range.
  • Patients who have undergone bilateral oophorectomy are eligible.
  • Post-menopausal status defined as either 1) at least 2 years without menstrual period or 2) patients older than 50 with serological evidence of post-menopausal status or 3) hysterectomized patients of any age with FSH confirmation of post-menopausal status.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • Biopsy proven diagnosis of HR+HER2- metastatic breast cancer. ER expression is >10%
  • Patient needs to be able to understand and demonstrate willingness to sign a written informed consent document
  • Hematological WBC ≥ 2000/uL
  • Absolute neutrophil count (ANC) ≥1500/µL
  • Platelets ≥100 000/µL
  • Hemoglobin ≥9.0 g/dL or ≥5.6 mmol/La Renal Creatinine OR Measured or calculated creatinine clearance (GFR can also be used in place of creatinine or CrCl) ≤1.5 × ULN OR ≥30 mL/min for participant with creatinine levels >1.5 × institutional ULN

Hepatic Total bilirubin ≤1.5 ×ULN OR direct bilirubin ≤ULN for participants with total bilirubin levels >1.5 × ULN

  • AST (SGOT) and ALT (SGPT) ≤2.5 × ULN
  • Coagulation International normalized ratio (INR) OR prothrombin time (PT)
  • Activated partial thromboplastin time (aPTT) ≤1.5 × ULN unless participant is receiving anticoagulant therapy if PT or aPTT is within therapeutic range of intended use of anticoagulants

Exclusion Criteria:

  • Active connective tissue disorders, such as lupus or scleroderma requiring flare therapy
  • Current use of systemic chemotherapy, endocrine therapy or HER2-neu targeted therapy
  • Male breast cancer patients
  • Any lesion >5 cm in greatest diameter.
  • Inability to obtain histologic proof of metastatic breast cancer
  • Has received previous endocrine or chemotherapy for metastatic breast cancer.
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.
  • Has a known additional malignancy (second primary) that is progressing or has required active treatment within the past 3 years. Note: - - - Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. cervical cancer in situ) that have undergone potentially curative therapy are not excluded.
  • Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  • Has an active infection requiring systemic therapy. Has a known history of Human Immunodeficiency Virus (HIV). Note: No HIV testing is required unless mandated by local health authority.
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  • Patients with uncontrolled brain metastases

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04220476


Sponsors and Collaborators
Weill Medical College of Cornell University
Investigators
Layout table for investigator information
Principal Investigator: Silvia Formenti, M.D. Weill Cornell Medicine
Layout table for additonal information
Responsible Party: Weill Medical College of Cornell University
ClinicalTrials.gov Identifier: NCT04220476    
Other Study ID Numbers: 19-09020752
First Posted: January 7, 2020    Key Record Dates
Last Update Posted: September 21, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Weill Medical College of Cornell University:
metastatic Breast cancer
HR+HER2-
HR + BC
SBRT
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Letrozole
Palbociclib
Antineoplastic Agents
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Protein Kinase Inhibitors